CommercialPrior AuthMedium impact
Ibandronate Sodium Injections (Revised)
Humana·Endocrinology, Internal Medicine, Geriatrics +2 more·Commercial
Effective date
Jun 26, 2024
We identified it
Jun 25, 2026
Summary
Humana revised its Ibandronate Sodium Injections prior authorization policy on June 26, 2024. The policy requires prior authorization for IV ibandronate (3 mg/3 mL vial or syringe) in postmenopausal women with osteoporosis who have failed or are intolerant to oral bisphosphonates. Key clinical requirements include documented bone loss despite prior treatment, adequate calcium/vitamin D supplementation, serum creatinine monitoring, pre-treatment oral exam, and consideration of atypical femur fracture risk for patients on bisphosphonates longer than 5 years.
Action Required
Before June 26, 2024 (or immediately if already past): Billing team must ensure all Ibandronate Sodium Injection claims (HCPCS J0897) for Humana commercial members require prior authorization submission. Update billing system workflows to flag claims without prior auth approval. Verify claims include documentation of: (1) postmenopausal osteoporosis diagnosis, (2) new fractures or significant bone mineral density loss despite prior oral bisphosphonate therapy, (3) evidence of contraindication or intolerance to oral bisphosphonates (e.g., inability to sit upright 30-60 minutes, swallowing difficulty, GI disorders), (4) serum creatinine measurement prior to injection, and (5) calcium/vitamin D supplementation plan (minimum 1200 mg calcium, 800-1000 IU vitamin D daily). For patients on bisphosphonates >5 years, ensure documentation acknowledges atypical femur fracture risk. Claims lacking these elements will be denied. Train providers to complete oral exams prior to treatment and monitor for severe bone, joint, or muscle pain. Update EMR templates and encounter forms to capture all prior authorization criteria.